Effects of Prospective Audit and Feedback in Patients with Extended-Spectrum β-Lactamase-Producing Escherichia coli Bacteremia

被引:0
|
作者
Yamada, Yota [1 ,2 ]
Miyazaki, Motoyasu [1 ,2 ,3 ]
Kushima, Hisako [2 ,4 ]
Hirata, Hitomi [1 ,2 ]
Ogawa, Arata [1 ,2 ]
Komiya, Yukie [2 ,5 ]
Hagiwara, Chika [1 ]
Nakashima, Akio [1 ,3 ]
Ishii, Hiroshi [2 ,4 ]
Imakyure, Osamu [1 ,3 ]
机构
[1] Fukuoka Univ, Chikushi Hosp, Dept Pharm, Fukuoka 8188502, Japan
[2] Fukuoka Univ, Chikushi Hosp, Dept Infect Control & Prevent, Fukuoka 8188502, Japan
[3] Fukuoka Univ, Dept Hosp Pharm, Fac Pharmaceut Sci, Fukuoka 8140180, Japan
[4] Fukuoka Univ, Chikushi Hosp, Dept Resp Med, Fukuoka 8188502, Japan
[5] Fukuoka Univ, Chikushi Hosp, Dept Clin Lab, Fukuoka 8188502, Japan
关键词
antimicrobial stewardship; prospective audit and feedback; extended-spectrum <italic>beta</italic>-lactamase-producing <italic>Escherichia coli</italic>; treatment failure rate; STEWARDSHIP PROGRAM GUIDELINES; INFECTIOUS-DISEASES SOCIETY; HEALTH-CARE EPIDEMIOLOGY; ANTIMICROBIAL STEWARDSHIP; ANTIBIOTIC-THERAPY; ENTEROBACTERIACEAE; IMPACT; PREVALENCE; CARRIAGE; OUTCOMES;
D O I
10.3390/microorganisms12112275
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Antimicrobial stewardship (AS) Guidelines by the Infectious Diseases Society of America recommend employing prospective audit and feedback (PAF) as an effective intervention in AS programs. Since July 2022, our hospital has implemented PAF for all patients with positive blood cultures, including those with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (EC) bacteremia. Our study examined the effect of PAF on clinical outcomes in patients with ESBL-EC bacteremia. We enrolled 62 patients diagnosed with ESBL-EC via blood culture who were undergoing antibiotic treatment. The patients were divided into the pre-PAF and post-PAF implementation groups. The rate of antibiotic de-escalation from broad-spectrum antibiotics to narrow-spectrum cefmetazole was significantly higher in the post-PAF group than in the pre-PAF group (80.7% vs. 32.4%, p = 0.0003). The treatment failure rate in the pre-PAF group was higher than that in the post-PAF group (38.7% vs. 12.9%, p = 0.04). The results of this study indicate that the implementation of PAF is advantageous not only in terms of process indicators but also in improved clinical outcomes, including reduced treatment failure rates. We hope that this study will encourage the implementation of PAF in more facilities to instigate a collective effort to reduce the incidence of antimicrobial resistance.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The first identification of an extended-spectrum β-lactamase-producing Escherichia coli from Norwegian livestock
    Sunde, M.
    Tharaldsen, H.
    Solheim, H.
    Norstroem, M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S272 - S272
  • [32] Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli in a remote region of Niger
    Jacquier, Herve
    Assao, Bachir
    Chau, Francoise
    Guindo, Ousmane
    Condamine, Benedicte
    Magnan, Melanie
    Bridier-Nahmias, Antoine
    Sayingoza-Makombe, Nathan
    Moumouni, Aissatou
    Page, Anne-Laure
    Langendorf, Celine
    Coldiron, Matthew E.
    Denamur, Erick
    de Lastours, Victoire
    JOURNAL OF INFECTION, 2023, 87 (03) : 199 - 209
  • [33] Risk Factors for Multidrug Resistance in Nosocomial Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
    Park, So Yeon
    Kang, Cheol-In
    Joo, Eun-Jeong
    Ha, Young Eun
    Wi, Yu Mi
    Chung, Doo Ryeon
    Peck, Kyong Ran
    Lee, Nam-Yong
    Song, Jae-Hoon
    MICROBIAL DRUG RESISTANCE, 2012, 18 (05) : 518 - 524
  • [34] Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli
    Bin, Cao
    Hui, Wang
    Zhu Renyuan
    Ning Yongzhong
    Xie Xiuli
    Xu Yingchun
    Zhu Yuanjue
    Chen Minjun
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 56 (04) : 351 - 357
  • [35] Risk Factors for Bloodstream Infections due to Extended-spectrum β-lactamase-producing Escherichia coli
    Wu, Un-In
    Yang, Ching-Shiang
    Chen, Wan-Chin
    Chen, Yee-Chun
    Chang, Shan-Chwen
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2010, 43 (04) : 310 - 316
  • [36] Polyclonal distribution of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Stockholm
    Titelman, E.
    Iversen, A.
    Lagergren, A.
    Kuhn, I.
    Kahlmeter, G.
    Giske, C.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S90 - S91
  • [37] Extended-spectrum β-lactamase-producing organisms
    Falagas, M. E.
    Karageorgopoulos, D. E.
    JOURNAL OF HOSPITAL INFECTION, 2009, 73 (04) : 345 - 354
  • [38] Extended-spectrum β-lactamase-producing Escherichia coli (vol 20, pg 404, 2020)
    Huang, Y.
    Zeng, L.
    Doi, Y.
    Lv, L.
    Liu, J-H
    LANCET INFECTIOUS DISEASES, 2020, 20 (08): : E180 - E180
  • [39] Epidemiology of Extended-Spectrum β-Lactamase-Producing Escherichia coli in the Human-Livestock Environment
    Nüesch-Inderbinen M.
    Stephan R.
    Current Clinical Microbiology Reports, 2016, 3 (1) : 1 - 9
  • [40] Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
    Wong-Beringer, A
    PHARMACOTHERAPY, 2001, 21 (05): : 583 - 592